TARGET AUDIENCE
This educational activity is intended for the multi-disciplinary care team (cardiologists, hematologists, hematologist-oncologists, nephrologists, geneticists, pathologists, neurologists, surgeons, and imagers), and other members of the health care team (nurses and PAs) who treat patients with amyloidosis.

PROGRAM OVERVIEW
This meeting series provides a comprehensive exploration of the challenges and strategies involved in diagnosing and managing amyloidosis. The curriculum emphasizes comparing evidence-based treatment options, applying best practices in care planning, and clarifying the distinct roles of clinical team members in patient management. Participants will explore monitoring strategies, assessment methods, and team-based approaches to address ongoing disease burden and optimize long-term outcomes.

Upon completion of this activity, the learners should be able to:

• Discuss standard and experimental treatment approaches for patients with AL amyloidosis

• List the role of different team members in managing a patient with AL amyloidosis

FACULTY

This activity is jointly provided by The France Foundation and the International Cardio-Oncology Society.

In support of improving patient care, The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

Physicians: The France Foundation designates this live activity for a maximum of 0.5  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: The France Foundation designates this activity for 0.5 nursing contact hours.

Physician Assistants: The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Pharmacists: This application-based activity (UAN # JA0007204-9999-25-089-H01-P), qualifies for 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

All other healthcare professionals completing this course will be issued a statement of participation.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The France Foundation (TFF) and International Cardio-Oncology society (IC-OS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. TFF and IC-OS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs.

Furthermore, TFF and IC-OS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and IC-OS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.

TFF and IC-OS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that are outside of US Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and IC-OS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

This activity is supported by an independent medical educational grant from Amyloidosis Foundation, Alnylam U.S., Inc, BridgeBio Pharma, Inc, and Janssen Scientific Affairs, LLC.

The France Foundation and IC-OS present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, IC-OS, and the commercial supporter(s) assume no liability for the information herein.